Rednex Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.25 Cr
as on 24-10-2024
- Paid Up Capital ₹ 4.25 Cr
as on 24-10-2024
- Company Age 4 Year, 17 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 16.25 Cr
as on 24-10-2024
- Revenue %
(FY 2023)
- Profit -1593.47%
(FY 2023)
- Ebitda -7361.22%
(FY 2023)
- Net Worth 6894.35%
(FY 2023)
- Total Assets 183.03%
(FY 2023)
About Rednex Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.25 Cr and a paid-up capital of Rs 4.25 Cr.
The company currently has active open charges totaling ₹16.25 Cr.
Aakashbhai Gangadiya, Chetanbhai Matholiya, and Jayeshbhai Sabava serve as directors at the Company.
- CIN/LLPIN
U24304GJ2020PTC119176
- Company No.
119176
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Dec 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Rednex Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aakashbhai Gangadiya  | Director | 29-Dec-2020 | Current |
| Chetanbhai Matholiya | Director | 29-Dec-2020 | Current |
| Jayeshbhai Sabava | Director | 29-Dec-2020 | Current |
Financial Performance of Rednex Pharmaceuticals.
Rednex Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 1593.47% decrease in profit. The company's net worth Soared by an impressive increase of 6894.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rednex Pharmaceuticals?
In 2023, Rednex Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Narayan Pharma House LlpActive 2 years 5 months
Chetanbhai Matholiya and Jayeshbhai Sabava are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 09 Sep 2022 | ₹16.25 Cr | Open |
How Many Employees Work at Rednex Pharmaceuticals?
Rednex Pharmaceuticals has a workforce of 27 employees as of May 14, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rednex Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rednex Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
